MCID: BRS049
MIFTS: 56

Breast Carcinoma in Situ

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 45 15
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD9CM 36 233.0
MeSH 45 D000071960
ICD10 34 D05 D05.9
UMLS 74 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to comedo carcinoma and lobular neoplasia. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Anastrozole and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.5 ERBB2 ESR1
2 lobular neoplasia 32.0 BRCA1 ERBB2 ESR1
3 ductal carcinoma in situ 30.5 BRCA1 BRCA2 ERBB2 ESR1 KRT5 PGR
4 in situ carcinoma 29.9 BRCA1 ERBB2 ESR1 KRT5 PGR TP53
5 breast ductal carcinoma 29.2 BRCA1 ERBB2 ESR1 MET PGR TP53
6 female breast cancer 28.9 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
7 ovarian cancer 28.2 BRCA1 BRCA2 ERBB2 ESR1 KDR MMP2
8 breast cancer 26.7 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
9 breast apocrine carcinoma in situ 11.9
10 pleomorphic adenoma carcinoma 10.5 ERBB2 TP53
11 vulvar intraepithelial neoplasia 10.5 MMP2 TP53
12 hereditary site-specific ovarian cancer syndrome 10.5 BRCA1 BRCA2
13 angiokeratoma circumscriptum 10.5 KDR VEGFA
14 critical limb ischemia 10.5 IL6 VEGFA
15 infiltrating angiolipoma 10.5 VEGFA VEGFC
16 acute transverse myelitis 10.4 IL6 MMP2
17 gorham's disease 10.4 FLT4 VEGFC
18 congenital lymphedema 10.4 FLT4 VEGFC
19 tuberculous salpingitis 10.4 BRCA1 BRCA2 ERBB2
20 oral cavity cancer 10.4 ERBB2 TP53 VEGFA
21 fallopian tube adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2
22 renal cell carcinoma, papillary, 1 10.4 ERBB2 MET TP53
23 uterine corpus serous adenocarcinoma 10.4 BRCA1 ERBB2 TP53
24 keratinizing squamous cell carcinoma 10.4 KRT5 TP53
25 mutagen sensitivity 10.4 BRCA1 BRCA2 TP53
26 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
27 respiratory system disease 10.3 IL6 TP53 VEGFA
28 intestinal disease 10.3 IL6 TP53 VEGFA
29 male reproductive system disease 10.3 IL6 TP53 VEGFA
30 tongue squamous cell carcinoma 10.3 MMP2 TP53 VEGFC
31 breast reconstruction 10.3 BRCA1 BRCA2
32 melanoma, uveal 10.3 MET MMP2 VEGFC
33 hereditary breast ovarian cancer syndrome 10.3 BRCA1 BRCA2 TP53
34 grade iii astrocytoma 10.3 MMP2 TP53 VEGFA
35 primary effusion lymphoma 10.3 IL6 MET VEGFA
36 tongue disease 10.2 MMP2 TP53 VEGFC
37 osteoporotic fracture 10.2 ESR1 IL6
38 angiosarcoma 10.2 FLT4 KDR VEGFA
39 hemifacial spasm 10.2 FLT4 VEGFA
40 stomach disease 10.2 ERBB2 MET TP53 VEGFA
41 lymphangiosarcoma 10.2 FLT4 VEGFA VEGFC
42 peritoneum cancer 10.2 BRCA1 BRCA2 KRT5
43 breast squamous cell carcinoma 10.2 ERBB2 KRT5 TP53
44 radiation proctitis 10.2 FGF2 KDR VEGFA
45 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
46 arteriovenous malformations of the brain 10.2 IL6 KDR VEGFA
47 breast malignant phyllodes tumor 10.2 PGR TP53
48 connective tissue cancer 10.2 FGF2 TP53 VEGFA
49 poems syndrome 10.2 FGF2 IL6 VEGFA
50 supratentorial cancer 10.2 KDR MMP2 TP53 VEGFA

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.64 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.64 BRCA1 ESR1 FGFR1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.64 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.64 ESR1 KDR
5 Decreased viability GR00301-A 9.64 BRCA1
6 Decreased viability GR00342-S-1 9.64 FLT4
7 Decreased viability GR00342-S-2 9.64 FLT4
8 Decreased viability GR00342-S-3 9.64 FLT4
9 Decreased viability GR00402-S-2 9.64 BRCA1 ESR1 FGFR1 FLT4 KDR
10 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
12 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
2 cellular MP:0005384 10.49 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
3 homeostasis/metabolism MP:0005376 10.49 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
4 growth/size/body region MP:0005378 10.48 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
5 behavior/neurological MP:0005386 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6 mortality/aging MP:0010768 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
7 digestive/alimentary MP:0005381 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
8 embryo MP:0005380 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
9 immune system MP:0005387 10.42 BRCA1 BRCA2 ESR1 FGFR1 FLT4 IL6
10 integument MP:0010771 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
11 endocrine/exocrine gland MP:0005379 10.4 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
12 hematopoietic system MP:0005397 10.38 BRCA1 BRCA2 ESR1 FGF2 FGFR1 IL6
13 muscle MP:0005369 10.32 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
14 nervous system MP:0003631 10.31 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
15 neoplasm MP:0002006 10.27 BRCA1 BRCA2 ERBB2 ESR1 FGF2 IL6
16 limbs/digits/tail MP:0005371 10.26 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6ST
17 craniofacial MP:0005382 10.21 ERBB2 FGFR1 KDR KRT5 MET MMP2
18 normal MP:0002873 10.21 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
19 liver/biliary system MP:0005370 10.16 ESR1 FLT4 IL6 IL6ST KDR LIF
20 adipose tissue MP:0005375 10.1 BRCA1 ESR1 FLT4 IL6 LIF TP53
21 no phenotypic analysis MP:0003012 10.1 ESR1 FGFR1 FLT4 KDR KRT19 KRT5
22 reproductive system MP:0005389 10.1 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
23 renal/urinary system MP:0005367 9.87 BRCA1 ESR1 FGFR1 IL6 MET TP53
24 respiratory system MP:0005388 9.85 BRCA1 ERBB2 ESR1 IL6 KDR LIF
25 skeleton MP:0005390 9.83 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
26 vision/eye MP:0005391 9.32 FGF2 FGFR1 IL6 IL6ST KDR LIF

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
2
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
3
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
5
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
6
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
7
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
8 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
22 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Chelating Agents Phase 4,Phase 3,Phase 2,Not Applicable
24
Trastuzumab Approved, Investigational Phase 3,Phase 2,Not Applicable 180288-69-1 9903
25
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
26
Norethindrone Approved Phase 3 68-22-4 6230
27
Polyestradiol phosphate Approved Phase 3,Phase 2 28014-46-2
28
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
29
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
30
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
32
Metformin Approved Phase 3,Phase 1 657-24-9 14219 4091
33
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
34
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Antineoplastic Agents, Immunological Phase 3,Phase 2,Not Applicable,Early Phase 1
37 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
38 Estradiol 3-benzoate Phase 3,Phase 2
39 Contraceptive Agents Phase 3,Early Phase 1
40 Estradiol 17 beta-cypionate Phase 3,Phase 2
41 Contraceptives, Oral Phase 3,Early Phase 1
42 Norethindrone Acetate Phase 3
43
Medroxyprogesterone Phase 3 520-85-4 10631
44 Contraceptive Agents, Male Phase 3
45 Anti-Allergic Agents Phase 3
46 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Dermatologic Agents Phase 3,Phase 2
48 Estrogens, Conjugated (USP) Phase 3,Phase 2
49 Narcotics Phase 3,Phase 2
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
4 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
6 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
7 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
14 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
17 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
18 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
19 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
20 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
21 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
22 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
25 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
26 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
27 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
28 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
29 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
30 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
31 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
32 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Completed NCT02556632 Phase 2 Curcumin-based Gel
33 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
34 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
35 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
37 Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Completed NCT00084539 Phase 2
38 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
39 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
40 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
41 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
42 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
43 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
44 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2 anastrozole
45 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed NCT00090857 Phase 2 Letrozole
46 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
47 Treatment With Pazopanib for Neoadjuvant Breast Cancer Completed NCT00849472 Phase 2 doxorubicin + cyclophosphamide;paclitaxel + pazopanib;pazopanib monotherapy
48 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
49 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
50 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2

Search NIH Clinical Center for Breast Carcinoma in Situ

Cochrane evidence based reviews: breast carcinoma in situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

42
Breast, Skin, Bone, Lymph Node, Prostate, Testes, Tongue

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

20
The Breast

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 48)
# Title Authors Year
1
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
2
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. ( 30025999 )
2018
3
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2017
4
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2017
5
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
6
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
7
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
8
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
9
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
10
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
11
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
12
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
13
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
14
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
15
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
16
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
17
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
18
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
19
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
20
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
21
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
22
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
23
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. ( 15841074 )
2005
24
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
25
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
26
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
27
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
28
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
29
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
30
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
31
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
32
Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. ( 11444192 )
2001
33
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
34
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
35
Risk of subsequent invasive breast cancer after breast carcinoma in situ. ( 10703809 )
2000
36
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
37
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
38
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
39
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
40
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
41
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
42
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
43
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
44
Breast carcinoma in situ. ( 20169700 )
1992
45
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
46
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
47
Breast carcinoma in situ. ( 2535929 )
1989
48
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 ERBB2 ESR1 FGF2 FGFR1 FLT4 IL6
2
Show member pathways
13.93 ERBB2 FGF2 FGFR1 FLT4 IL6 IL6ST
3
Show member pathways
13.9 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT4
4
Show member pathways
13.73 ERBB2 FGFR1 FLT4 IL6 IL6ST KDR
5
Show member pathways
13.69 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6
Show member pathways
13.61 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
7
Show member pathways
13.59 BRCA1 ERBB2 FGF2 FGFR1 FLT4 IL6
8
Show member pathways
13.56 ERBB2 FGF2 FGFR1 KDR KRT19 KRT5
9
Show member pathways
13.47 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
10
Show member pathways
13.41 ERBB2 FGF2 FGFR1 IL6 IL6ST LIF
11
Show member pathways
13.38 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
12
Show member pathways
13.37 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
13
Show member pathways
13.35 ERBB2 ESR1 FGF2 FGFR1 FLT4 IL6
14
Show member pathways
13.14 FGF2 FGFR1 FLT4 IL6 KDR MET
15
Show member pathways
13.11 FGF2 FGFR1 FLT4 IL6 KDR MET
16
Show member pathways
13.09 ESR1 KRT19 MMP2 PGR VEGFA VEGFC
17
Show member pathways
12.96 ERBB2 FLT4 KDR MET VEGFA VEGFC
18
Show member pathways
12.91 BRCA2 ERBB2 FGFR1 TP53 VEGFA
19
Show member pathways
12.9 ERBB2 FGFR1 IL6 IL6ST LIF
20
Show member pathways
12.9 BRCA1 ERBB2 FGF2 FGFR1 FLT4 IL6
21
Show member pathways
12.82 FGF2 FGFR1 FLT4 KDR MET VEGFA
22
Show member pathways
12.79 FGF2 FGFR1 FLT4 IL6 KDR MET
23
Show member pathways
12.78 ERBB2 FGF2 FGFR1 MET TP53
24 12.78 ERBB2 FGF2 FGFR1 FLT4 KDR MET
25
Show member pathways
12.65 ERBB2 FGF2 IL6 MMP2 TP53
26
Show member pathways
12.62 ERBB2 MET TP53 VEGFA
27
Show member pathways
12.62 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
28
Show member pathways
12.59 ERBB2 FGFR1 FLT4 KDR MET TP53
29 12.57 BRCA1 ERBB2 MET TP53 VEGFA
30
Show member pathways
12.54 ERBB2 FGFR1 FLT4 KDR MET TP53
31
Show member pathways
12.5 FGF2 FGFR1 FLT4 KDR MET VEGFA
32
Show member pathways
12.49 ERBB2 FGF2 FGFR1 FLT4 IL6 KDR
33
Show member pathways
12.45 BRCA1 ESR1 KDR VEGFA
34
Show member pathways
12.36 FGF2 FGFR1 IL6 TP53
35
Show member pathways
12.34 FGF2 FGFR1 FLT4 IL6 KDR MET
36
Show member pathways
12.33 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
37
Show member pathways
12.32 FGF2 FGFR1 KDR VEGFA VEGFC
38
Show member pathways
12.31 ERBB2 FGFR1 FLT4 IL6ST KDR MET
39 12.25 IL6 MMP2 TP53 VEGFA
40 12.25 BRCA1 BRCA2 ESR1 TP53 VEGFA
41
Show member pathways
12.19 ERBB2 IL6 IL6ST MMP2
42 12.19 ERBB2 FGFR1 FLT4 IL6ST KDR MET
43 12.16 KDR MMP2 TP53 VEGFA
44 12.16 FGF2 FGFR1 IL6ST LIF
45
Show member pathways
12.16 BRCA1 FGF2 FGFR1 FLT4 IL6 KDR
46 12.16 BRCA2 ERBB2 ESR1 FGF2 FGFR1 FLT4
47 12.13 LIF MET MMP2 TP53
48 12.12 KDR MMP2 TP53 VEGFA
49 12.12 ERBB2 FGF2 FGFR1 FLT4 KDR MET
50 12.11 ERBB2 ESR1 FGF2 FGFR1 KDR MET

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 FGF2 FGFR1 FLT4 IL6 IL6ST KDR
2 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6ST
3 receptor complex GO:0043235 9.1 ERBB2 FGFR1 FLT4 IL6ST KDR MET

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.98 ERBB2 FGFR1 FLT4 KDR
2 positive regulation of protein kinase B signaling GO:0051897 9.97 ERBB2 ESR1 FGF2 FGFR1 MET
3 positive regulation of angiogenesis GO:0045766 9.95 BRCA1 FGF2 KDR VEGFA VEGFC
4 cytokine-mediated signaling pathway GO:0019221 9.95 FGF2 IL6 IL6ST LIF MMP2 TP53
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 ERBB2 FLT4 KDR MET
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 IL6 LIF TP53 VEGFA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 IL6 IL6ST LIF VEGFA
8 lung development GO:0030324 9.89 FGFR1 LIF VEGFA
9 positive regulation of MAP kinase activity GO:0043406 9.89 ERBB2 FGF2 FGFR1 VEGFA
10 cell differentiation GO:0030154 9.89 FGF2 KDR TP53 VEGFA VEGFC
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 IL6 LIF VEGFA
12 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 FLT4 KDR VEGFA VEGFC
13 response to estrogen GO:0043627 9.87 BRCA1 ESR1 KRT19
14 positive regulation of epithelial cell proliferation GO:0050679 9.87 ERBB2 VEGFA VEGFC
15 angiogenesis GO:0001525 9.87 FGF2 FGFR1 FLT4 KDR MMP2 VEGFA
16 positive regulation of endothelial cell migration GO:0010595 9.86 FLT4 KDR VEGFA
17 positive regulation of cell division GO:0051781 9.85 FGF2 VEGFA VEGFC
18 peptidyl-tyrosine phosphorylation GO:0018108 9.85 ERBB2 FGFR1 FLT4 KDR MET
19 positive chemotaxis GO:0050918 9.84 FGF2 MET VEGFA VEGFC
20 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.83 FGF2 KDR VEGFA
21 regulation of angiogenesis GO:0045765 9.83 ERBB2 FGF2 IL6
22 lung alveolus development GO:0048286 9.83 FLT4 LIF PGR
23 positive regulation of endothelial cell proliferation GO:0001938 9.83 FGF2 FLT4 KDR VEGFA VEGFC
24 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.82 FLT4 KDR VEGFA
25 sprouting angiogenesis GO:0002040 9.82 FLT4 VEGFA VEGFC
26 positive regulation of vascular endothelial growth factor production GO:0010575 9.81 BRCA1 FLT4 IL6ST
27 cell migration involved in sprouting angiogenesis GO:0002042 9.79 FGF2 KDR VEGFA
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.74 BRCA1 BRCA2 TP53
29 positive regulation of phospholipase C activity GO:0010863 9.73 ESR1 FGF2 FGFR1
30 induction of positive chemotaxis GO:0050930 9.72 VEGFA VEGFC
31 positive regulation of acute inflammatory response GO:0002675 9.71 IL6 IL6ST
32 positive regulation of astrocyte differentiation GO:0048711 9.71 IL6ST LIF
33 positive regulation of positive chemotaxis GO:0050927 9.71 KDR VEGFA
34 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.71 ESR1 TP53
35 positive regulation of endothelial cell chemotaxis GO:2001028 9.7 FGF2 MET
36 positive regulation of protein kinase C signaling GO:0090037 9.7 FLT4 VEGFA
37 paracrine signaling GO:0038001 9.69 FGF2 PGR
38 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.69 FGF2 FLT4 KDR
39 positive regulation of mast cell chemotaxis GO:0060754 9.68 VEGFA VEGFC
40 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.68 KDR VEGFA
41 leukemia inhibitory factor signaling pathway GO:0048861 9.67 IL6ST LIF
42 vascular endothelial growth factor signaling pathway GO:0038084 9.67 FLT4 KDR VEGFA VEGFC
43 positive regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000546 9.66 FGF2 FGFR1
44 chordate embryonic development GO:0043009 9.65 BRCA1 BRCA2 FGFR1
45 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 FGF2 FGFR1 KDR VEGFA VEGFC
46 negative regulation of apoptotic process GO:0043066 9.63 FLT4 IL6 IL6ST KDR TP53 VEGFA
47 positive regulation of cell proliferation GO:0008284 9.61 FGF2 FGFR1 FLT4 IL6 IL6ST KDR
48 positive regulation of MAPK cascade GO:0043410 9.1 ERBB2 FGFR1 FLT4 IL6 KDR LIF
49 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 BRCA1 ESR1 FGF2 IL6 LIF MET
50 positive regulation of transcription, DNA-templated GO:0045893 10.15 BRCA1 BRCA2 ESR1 FGF2 IL6 TP53

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.95 ERBB2 FGFR1 FLT4 KDR MET
2 cytokine activity GO:0005125 9.84 FGF2 IL6 LIF VEGFA
3 growth factor activity GO:0008083 9.77 FGF2 IL6 LIF VEGFA VEGFC
4 protein phosphatase binding GO:0019903 9.71 ERBB2 FLT4 MET TP53
5 identical protein binding GO:0042802 9.65 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 KDR
6 chemoattractant activity GO:0042056 9.63 FGF2 VEGFA VEGFC
7 growth factor binding GO:0019838 9.62 ERBB2 FLT4 IL6ST KDR
8 protein tyrosine kinase activity GO:0004713 9.55 ERBB2 FGFR1 FLT4 KDR MET
9 interleukin-6 receptor binding GO:0005138 9.52 IL6 IL6ST
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.51 FLT4 KDR
11 receptor-receptor interaction GO:0090722 9.48 FGF2 FGFR1
12 vascular endothelial growth factor receptor 3 binding GO:0043185 9.19 VEGFC
13 transmembrane signaling receptor activity GO:0004888 9.13 ERBB2
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 ERBB2 FGFR1 FLT4 KDR MET
15 protein binding GO:0005515 10.23 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....